News & Events about Belite Bio Inc Adr.
Globe Newswire
2 months ago
Tinlarebant (a/k/a LBS-008) is Belite Bios orally administered tablet intended as an early intervention to slow disease progression in patients affected with Stargardt Disease (STGD1) and Dry Age-related Macular Degeneration (Dry AMD)There are currently no approved treatments for STGD1 and Dry ...
Globe Newswire
4 months ago
1-year interim data from the 2-year Phase 1b/2 trial of LBS-008 in adolescent STGD1 to be presented SAN DIEGO, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases, ...
Globe Newswire
4 months ago
LBS-008 (aka Tinlarebant) is Belite Bios orally administered tablet for early intervention to maintain the health of retinal tissue in Stargardt disease (STGD1) and Dry AMD patientsA 2-year Phase 2 trial in adolescent STGD1 and a global Phase 3 trial in adolescent STGD1 are ongoingThe Phase 3 trial ...
Globe Newswire
5 months ago
LBS-008 (aka Tinlarebant) is Belite Bios orally administered tablet for the treatment of Stargardt disease (STGD1) and Dry AMDA 2-year Phase 2 trial in adolescent STGD1 and a global Phase 3 trial in adolescent STGD1 are ongoingThe Phase 3, Multi-center, Randomized, Double Masked, Placebo Controlled ...
Globe Newswire
6 months ago
-LBS-008 (aka Tinlarebant) is Belite Bios orally administered tablet for the treatment of Stargardt disease (STGD1) and Dry AMD-A 2-year Phase 2 trial in adolescent STGD1 and a global Phase 3 trial in adolescent STGD1 are ongoing-The Phase 3, Multicenter, Randomized, Double Masked, Placebo ...